ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

418
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
bullishTencent
23 Dec 2023 18:43

HK Connect SOUTHBOUND Flows (To 22Dec23); CNOOC/Energy To The Buy Side; Tencent Heavily Sold, Again.

In HK Connect, SOUTHBOUND flows this week were slightly positive but the big story was a big sell of Tencent and buying of ETFs. On average, liquid...

Logo
721 Views
Share
22 Dec 2023 14:00

Hong Kong Buybacks Weekly (Dec 22nd): Tencent, Aia, Li Ning

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
729 Views
Share
17 Dec 2023 19:09

HK Connect SOUTHBOUND Flows (To 15Dec23); CNOOC/Telecom/Mobile All Now To The Buy Side, Tencent NOT

SOUTHBOUND HK Connect Flows were lower than previous weeks in stock-picking but flows on ETFs were significant. NET flows were HK$9.9bn to the sell...

Logo
492 Views
Share
17 Dec 2023 10:05

HK Short Interest Weekly: JD, Microport, Wuxi Apptec, AIA

We analyzed the latest HK SFC report for aggregate short position as of Dec 8th and highlight short interest changes in Jd, Tracker Fund,...

Logo
366 Views
Share
x